References
1. Zubin MB, Ronald PD. Updates on the management of gastrointestinal stromal tumors. Surg Oncol Clin N Am . 2012;21(2):301-316.
2. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science.2003;299(5607):708-710.
3. Dematteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol . 2002;33(5):466-477.
4. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factor for survival. Ann Surg . 2000;231(1):51-58.
5. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg . 2006;44(2):176-184.
6. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol . 2005;55(4):379-386.
7. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther . 2000;295(1):139-145.
8. Delbaldo C, Chatelut E, Ré M, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res . 2006;12(20):6073-6078.
9. Rutkowski P, Ziętek M, Cybulska-Stopa B, et al. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice. Eur J Surg Oncol . 2021;47(5):1191-1195.
10. Li J, Gong JF, Wu AW, Shen L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol . 2011;37(4):319-324.
11. Joensuu H, Eriksson M, Hall KS, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA . 2012;307(12):1265-72.
12. Qi J, Liu HL, Ren F, et al. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study. World J Surg Oncol . 2020;18(1):70.
13. Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.J Clin Oncol. 2014;32(15):1563-70.
14. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med . 2002;347:472-80.
15. Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol . 2003;22:3275.
16. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol , 2008;26:620-625.
17. Xia YZ, Chen SL, Luo MJ, et al. Correlations Between Imatinib Plasma Trough Concentration and Adverse Reactions in Chinese Patients with Gastrointestinal Stromal Tumors. Cancer ,2020;126:2054-2061.
18. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol . 2009;27(19):3141-3147.
19. Guilhot F, Hughes TP, Cortes J, et al. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica . 2012;97(5):731-738.
20. Li J, Ye Y, Wang J, et al. Chinese Society Of Clinical Oncology Csco Expert Committee On Gastrointestinal Stromal Tumor. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res . 2017;29(4):281-293.
21. FDA [Internet]. Guidance for industry: bioanalytical method validation; [cited May 24, 2018]. Available from: https://www.fda. gov/downloads/drugs/guidances/ucm070107.Pdf. Accessed October 19, 2021.
22. Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic & clinical pharmacology & toxicology policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2018;123(3):233-235.
23. Bouchet S, Poulette S, Titier K, et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. Eur J Cancer . 2016,57:31-38.
24. Wu X, Li J, Zhou Y, et al. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor. Chemotherapy . 2018; 63(6): 301-307.
25. Koo DH, Ryu MH, Ryoo BY, et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients withgastrointestinal stromal tumor. Cancer Chemoth Pharm . 2015;75(1):173-182.
26. Lv M, Wu C, Zheng Y, Zhao NQ. Incidence and Survival Analysis of Gastrointestinal Stromal Tumors in Shanghai: A Population-Based Study from 2001 to 2010. Gastroent Res Pract. 2014;4(23):834136.
27. Darbalaei S, Zhang XL,Wang NX, et al. Effects of aprepitant on the pharmacokinetics of imatinib and its main metabolite in rats. Die Pharmazie . 2018;73(6): 329-334.
28. Vasconcelos FC, Bonecker ST, de Souza PS, et al. Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients. Leukemia Res . 2019;82: 33-35.
29. Valsangkar N, Sehdev A, Misra S, Zimmers TA, O’Neil BH, Koniaris LG. Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy. Surgery.2015;158(5):1149-1164.
30. Li J, Gong JF, Li J, Gao J, Sun NP, Shen L. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.World J Gastroenterol . 2012;18(7):698-703.
31. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Onco . 2008;26(4):626-32.
32. Yoo C, Ryu MH, Jo J, Park I, Ryoo BY, Kang YK. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors. Cancer Res Treat . 2016;48(2):546-52.
33. Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer . 2010;116(1):184-92.
34. Ben Ami E, Demetri GD. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opin Drug Saf . 2016;15(4): 571-578.